NEW YORK (GenomeWeb News) - Genomic Health said today that its predictive breast cancer assay has been included in the National Comprehensive Cancer Network’s 2008 Breast Cancer Treatment Guidelines.
 
The company’s Oncotype DX is a multi-gene expression test used to predict the chances of breast cancer recurrence and the likelihood that chemotherapy will benefit certain patients, the company said.
 
NCCN is an alliance of 21 cancer centers aimed at improving care and treatments for cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.